Reading is good for you...
Reading about what's good for you is even better.
December 18, 2023
December 14, 2023
August 8, 2022
Prescription required
Get your Vitrakvi delivered at your door for FREE
Vitrakvi (Larotrectinib) belongs to a group of cancer-fighting medications called protein kinase inhibitors. It works by recognizing certain types of cancer cells and blocking the action of chemicals that cause them to divide and grow.
Get Vitrakvi
Save Time. Skip the Line. Join Pocketpills and fill your prescriptions online
Medication pricing not available right now.
Please message us or give us a call at 1-855-950-7225.
Vitrakvi (Larotrectinib) belongs to a group of cancer-fighting medications called protein kinase inhibitors. It works by recognizing certain types of cancer cells and blocking the action of chemicals that cause them to divide and grow. This may slow down or stop cancers from growing and dividing.
Vitrakvi (Larotrectinib) may be used for solid (cancerous) tumours that have spread to other parts of the body (metastasized) or for which surgery is not appropriate, or that have a specific genetic change known as Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, and there are no other satisfactory treatments available.
Vitrakvi (Larotrectinib) has been granted a notice of compliance with conditions (NOC/c) by Health Canada. This means that Health Canada has approved Vitrakvi (Larotrectinib) to be marketed based on promising evidence of effectiveness, but additional results of studies are needed to verify its effectiveness. An NOC/c is used to allow access to products that are used to treat or prevent serious, life-threatening, or severely debilitating illness.
Vitrakvi (Larotrectinib) may be available under multiple brand names and/or in several different forms. Any specific brand name of Vitrakvi (Larotrectinib) may not be available in all of the forms or approved for all of the conditions discussed here. As well, some forms of Vitrakvi (Larotrectinib) may not be used for all of the conditions discussed here.
Your doctor may have suggested Vitrakvi (Larotrectinib) for conditions other than those listed in these drug information articles. If you have not discussed this with your doctor or are not sure why you are taking Vitrakvi (Larotrectinib), speak to your doctor. Do not stop taking Vitrakvi (Larotrectinib) without consulting your doctor.
Do not give Vitrakvi (Larotrectinib) to anyone else, even if they have the same symptoms as you do. It can be harmful for people to take Vitrakvi (Larotrectinib) if their doctor has not prescribed it.
The usual adult dose of Vitrakvi (Larotrectinib) is 100 mg taken by mouth, twice a day.
Doses for children are based on the child's body size, specifically the body surface area (BSA). The recommended dose for children is 100 mg per square metre of body surface area and will be calculated by your child's doctor. The maximum dose for children is 100 mg taken twice a day.
Vitrakvi (Larotrectinib) may be taken with food or on an empty stomach. Swallow the capsules whole with some fluid. Do not open, crush, chew, or dissolve the capsules to take them.
Use an oral syringe to measure each dose of the liquid, as this gives a more accurate measurement than household teaspoons.
Many things can affect the dose of medication that a person needs, such as body weight, other medical conditions, and other medications. If your doctor has recommended a dose different from the ones listed here, do not change the way that you are taking the medication without consulting your doctor.
It is important to take Vitrakvi (Larotrectinib) exactly as prescribed by your doctor. If you miss a dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. If you are not sure what to do after missing a dose, contact your doctor or pharmacist for advice.
If you vomit after taking a dose, take your next dose at the regularly scheduled time. Do not replace the vomited dose.
Store the capsule form of Vitrakvi (Larotrectinib) at room temperature in its original package, protect it from light and moisture, and keep it out of the reach of children. The oral solution should be stored in the refrigerator. Do not freeze. Discard the bottle 30 days after opening.
Do not dispose of medications in wastewater (e.g. down the sink or in the toilet) or in household garbage. Ask your pharmacist how to dispose of medications that are no longer needed or have expired.
Many medications can cause side effects. A side effect is an unwanted response to a medication when it is taken in normal doses. Side effects can be mild or severe, temporary or permanent.
The side effects listed below are not experienced by everyone who takes Vitrakvi (Larotrectinib). If you are concerned about side effects, discuss the risks and benefits of Vitrakvi (Larotrectinib) with your doctor.
The following side effects have been reported by at least 1% of people taking Vitrakvi (Larotrectinib). Many of these side effects can be managed, and some may go away on their own over time.
Contact your doctor if you experience these side effects and they are severe or bothersome. Your pharmacist may be able to advise you on managing side effects.
Although most of the side effects listed below don't happen very often, they could lead to serious problems if you do not seek medical attention.
Check with your doctor as soon as possible if any of the following side effects occur:
Stop taking the medication and seek immediate medical attention if any of the following occur:
Some people may experience side effects other than those listed. Check with your doctor if you notice any symptom that worries you while you are taking Vitrakvi (Larotrectinib).
Capsule
25 mg
Each white opaque, hard gelatin capsule (size 2) with blue printing of "BAYER" cross and "25 mg" on the body of capsule, contains 25 mg of Vitrakvi (Larotrectinib). Nonmedicinal ingredients: gelatin printing ink (shellac, FD&C Blue No. 2 Aluminum Lake, titanium dioxide, propylene glycol, ammonia solution, dimethicone), and titanium dioxide.
100 mg
Each white opaque, hard gelatin capsule (size 0) with blue printing of "BAYER" cross and "100 mg" on the body of capsule, contains 100 mg of Vitrakvi (Larotrectinib). Nonmedicinal ingredients: gelatin printing ink (shellac, FD&C Blue No. 2 Aluminum Lake, titanium dioxide, propylene glycol, ammonia solution, dimethicone), and titanium dioxide.
Oral Solution
20 mg/mL
Each mL of clear yellow to orange liquid solution contains 20 mg of Vitrakvi (Larotrectinib). Nonmedicinal ingredients: bitterness masking flavour (propylene glycol, natural flavour), taste modifier flavour (propylene glycol, glycerol, natural flavour), hydroxypropyl betadex, natural bitterness masking type flavour (glycerol, natural flavor ingredients), natural masking type flavour (glycerol, natural flavour ingredients), Ora-SweetÒ (purified water, sucrose, glycerol, sorbitol, citric acid, sodium dihydrogen phosphate, flavouring and preservative agents methylparahydroxybenzoate and potassium sorbate), purified water, and sodium citrate.
Do not take Vitrakvi (Larotrectinib) if you are allergic to Vitrakvi (Larotrectinib) or any ingredients of the medication.
There may be an interaction between Vitrakvi (Larotrectinib) and any of the following:
If you are taking any of these medications, speak with your doctor or pharmacist. Depending on your specific circumstances, your doctor may want you to:
An interaction between two medications does not always mean that you must stop taking one of them. Speak to your doctor about how any drug interactions are being managed or should be managed.
Medications other than those listed above may interact with Vitrakvi (Larotrectinib). Tell your doctor or prescriber about all prescription, over-the-counter (non-prescription), and herbal medications you are taking. Also tell them about any supplements you take. Since caffeine, alcohol, the Nicotine from cigarettes, or street drugs can affect the action of many medications, you should let your prescriber know if you use them.
Before you begin using a medication, be sure to inform your doctor of any medical conditions or Allergies you may have, any medications you are taking, whether you are pregnant or breast-feeding, and any other significant facts about your health. These factors may affect how you should use Vitrakvi (Larotrectinib).
Drowsiness/reduced alertness: Vitrakvi (Larotrectinib) may cause drowsiness or dizziness, affecting your ability to drive or operate machinery. Avoid driving, operating machinery, or performing other potentially hazardous tasks until you have determined how you are affected by Vitrakvi (Larotrectinib).
Kidney function: Kidney Disease or reduced kidney function may cause Vitrakvi (Larotrectinib) to build up in the body, causing side effects. If you have kidney problems, discuss with your doctor how Vitrakvi (Larotrectinib) may affect your medical condition, how your medical condition may affect the dosing and effectiveness of Vitrakvi (Larotrectinib), and whether any special monitoring is needed. Your doctor may want to test your liver function regularly with blood tests while you are taking Vitrakvi (Larotrectinib).
Liver function: Liver disease or reduced liver function may cause Vitrakvi (Larotrectinib) to build up in the body, causing side effects. If you have liver problems, discuss with your doctor how Vitrakvi (Larotrectinib) may affect your medical condition, how your medical condition may affect the dosing and effectiveness of Vitrakvi (Larotrectinib), and whether any special monitoring is needed. Your doctor may want to test your liver function regularly with blood tests while you are taking Vitrakvi (Larotrectinib).
Pregnancy: Vitrakvi (Larotrectinib) should not be used during pregnancy unless the benefits outweigh the risks. Women of childbearing age who are taking Vitrakvi (Larotrectinib) and women whose partners are taking Vitrakvi (Larotrectinib), should use an effective method of birth control, such as condoms, during treatment and for at least 1 month after stopping the medication. If you become pregnant while taking Vitrakvi (Larotrectinib), contact your doctor immediately.
Breast-feeding: It is not known if Vitrakvi (Larotrectinib) passes into breast milk. If you are a breast-feeding mother and are taking Vitrakvi (Larotrectinib), it may affect your baby. Talk to your doctor about whether you should continue breast-feeding.
Children: The safety and effectiveness of using Vitrakvi (Larotrectinib) have not been established for infants less than one month of age.
References
All material © 1996-2021 MediResource Inc. Terms and conditions of use. The contents herein are for informational purposes only. Always seek the advice of your physician or other qualified health providers with any questions you may have regarding a medical condition.
December 18, 2023
December 14, 2023
August 8, 2022